What do systematic reviews say?

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 0.87 [0.56, 1.33]
  23 studies · 32894 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.65]
  2 studies · 1108 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.59, 1.11]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fluorides combined with CPP-ACP vs Fluorides alone (monotherapy)

Adding CPP-ACP to fluorides did not significantly change QLF outcomes for smooth-surface early caries lesions versus fluorides alone; not GRADE-rated.

• Efficacy of fluorides and CPP-ACP vs fluorides monotherapy on early caries lesions: A systematic review and… 2018 All outcomes

  Post-treatment (4-12 weeks) · In vivo clinical trial (human oral cavity; smooth-surface early caries lesions) · Location of lesions: smooth surfaces
  MD 0.26 [-0.50, 1.01]
  2 studies
  GRADE not reported

Fluorides combined with CPP-ACP vs Fluorides alone (monotherapy)

Two trials reported visual inspection scores but could not be pooled (different criteria, missing standard deviations) and gave inconsistent findings, so no quantitative conclusion could be drawn.

• Efficacy of fluorides and CPP-ACP vs fluorides monotherapy on early caries lesions: A systematic review and… 2018 All outcomes

  Post-treatment (4-24 weeks) · In vivo clinical trial (human oral cavity)
  Not pooled (2 trials, different scoring criteria, standard deviations not reported). Brochner 2011: no significant difference; Andersson 2007: more lesions became invisible with fluorides + CPP-ACP.
  2 studies
  GRADE not reported

Fluorides combined with CPP-ACP vs Fluorides alone (monotherapy)

For occlusal early caries lesions, adding CPP-ACP to fluorides produced significantly greater laser-fluorescence improvement than fluorides alone (favors the combination); not GRADE-rated.

• Efficacy of fluorides and CPP-ACP vs fluorides monotherapy on early caries lesions: A systematic review and… 2018 All outcomes

  Post-treatment (3-12 weeks) · In vivo clinical trial (human oral cavity; occlusal early caries lesions) · Location of lesions: occlusal surfaces
  MD -21.02 [-27.94, -14.10]
  3 studies
  GRADE not reported
• Efficacy of fluorides and CPP-ACP vs fluorides monotherapy on early caries lesions: A systematic review and… 2018 All outcomes

  Post-treatment (12-24 weeks) · In vivo clinical trial (human oral cavity; smooth-surface early caries lesions) · Location of lesions: smooth surfaces
  MD -13.90 [-39.25, 11.46]
  4 studies
  GRADE not reported

Laparoscopy vs laparotomy

Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer 2018 · Cochrane Headline outcomes only
  HR 1.04 [0.86, 1.25]
  6 studies · 3993 participants
  Moderate

Laparoscopy vs laparotomy

Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer 2018 · Cochrane Headline outcomes only
  HR 1.14 [0.9, 1.43]
  5 studies · 3710 participants
  Moderate

Laparoscopy vs laparotomy

Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).

• Laparoscopy versus laparotomy for the management of early stage endometrial cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 313 participants
  Low